This analysis examines the market position and future outlook for MedImmune. The profile encompasses global and US specific company strategy, portfolio and pipeline analysis and assessment of financial performance, with US, rest of world and global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information

• Assess the impact of the termination of FluMist's co-promotion with Wyeth on MedImmune's future performance
• Benchmark MedImmune's performance against key rivals in the biotechnology sector
• Understand how MedImmune's follow up product for Synagis, Numax, will drive growth to 2010